- Home
- EVTL vs ANL Comparison
EVTL vs ANL Comparison
Compare EVTL & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVTL
- ANL
- Stock Information
- Founded
- EVTL 2016
- ANL 2004
- Country
- EVTL United Kingdom
- ANL Cayman Islands
- Employees
- EVTL N/A
- ANL N/A
- Industry
- EVTL Aerospace
- ANL
- Sector
- EVTL Industrials
- ANL
- Exchange
- EVTL Nasdaq
- ANL Nasdaq
- Market Cap
- EVTL 91.5M
- ANL 79.0M
- IPO Year
- EVTL N/A
- ANL 2023
- Fundamental
- Price
- EVTL $9.29
- ANL $2.05
- Analyst Decision
- EVTL Buy
- ANL Strong Buy
- Analyst Count
- EVTL 4
- ANL 2
- Target Price
- EVTL $10.33
- ANL $9.00
- AVG Volume (30 Days)
- EVTL 345.6K
- ANL 13.8K
- Earning Date
- EVTL 03-13-2025
- ANL 02-24-2025
- Dividend Yield
- EVTL N/A
- ANL N/A
- EPS Growth
- EVTL N/A
- ANL N/A
- EPS
- EVTL N/A
- ANL N/A
- Revenue
- EVTL N/A
- ANL $5,000,000.00
- Revenue This Year
- EVTL N/A
- ANL N/A
- Revenue Next Year
- EVTL N/A
- ANL N/A
- P/E Ratio
- EVTL N/A
- ANL N/A
- Revenue Growth
- EVTL N/A
- ANL N/A
- 52 Week Low
- EVTL $3.55
- ANL $1.85
- 52 Week High
- EVTL $15.99
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- EVTL 50.12
- ANL 44.92
- Support Level
- EVTL $7.76
- ANL $2.00
- Resistance Level
- EVTL $10.65
- ANL $2.19
- Average True Range (ATR)
- EVTL 1.80
- ANL 0.27
- MACD
- EVTL -0.31
- ANL -0.01
- Stochastic Oscillator
- EVTL 18.59
- ANL 16.81
About EVTL Vertical Aerospace Ltd.
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a global aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero operating emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.